|Bid||0.8500 x 900|
|Ask||0.8898 x 900|
|Day's Range||0.8100 - 0.8799|
|52 Week Range||0.8100 - 3.0300|
|Beta (5Y Monthly)||-1.58|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar. 23, 2022 - Mar. 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||4.56|
Investors need to pay close attention to Athersys (ATHX) stock based on the movements in the options market lately.
CLEVELAND, November 30, 2021--Publication of Athersys clinical trial results show MultiStem cell therapy support potential benefits for ARDS patients, including lower mortality.
Athersys, Inc. (ATHX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).